Since inhibition of the PI3K/AKT/mTOR pathway exhibits great antitumor effects against lung cancer, a variety of pan-PI3K inhibitors, selective PI3K inhibitors, AKT inhibitors, mTOR inhibitors, and dual PI3K-mTOR inhibitors have been developed in clinical trials [15,16]. This evidence concerns the gene AKT1 and lung cancer.